The Indian Council of Medical Research (ICMR) has given approval to convalescent plasma therapy in Kerala.
The experimental therapy can become a ray of light and hope with its success. Researchers and scientists are working tirelessly to invent or develop the vaccine which will provide the proper treatment. However, it is not yet clear if the Convalescent Plasma therapy can win over the virus but it can help the body to fight and overcome.
A patient needs only one dose to get enough antibodies and the donor can produce two doses. However, there are a very limited number of donors and the Convalescent Plasma therapy is expensive.
Amid testing the already testing drugs and new ones, researchers have come across to the convalescent plasma therapy.
What is convalescent plasma therapy and how it works?
The entire world is studying to develop the vaccine to cure COVID-19, China and some other countries, have already initiated the clinical trials.
Different countries are already trying to test the effectiveness of convalescent plasma therapy.
The therapy takes antibodies from the blood of a person who has recovered from a virus and then it is transferred into a person sick with that virus.
Basically, we can say immunity is transferred to boost the immune system of the sick through the plasma therapy.
The antibodies present in the plasma of the recovered patient help in neutralising the SARS-CoV-2 virus in the infected patient.
China has said that patients have shown significant improvement after Convalescent Plasma therapy was administrated in the trial.
The Convalescent plasma therapy was first used during the 1918 Spanish Influenza outbreak.
The technique was used previously during the outbreak of SARS, MERS and Ebola viruses.
How does Convalescent Plasma therapy works?
- It provides antibodies to a person to fight with the virus.
- Convalescent Plasma therapy consists of antibodies and proteins developed by the immune system to prevent the body from harm.
In India, only critical patients will get Plasma therapy.
The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) will soon begin with the trials by April end. With this Kerala will become the first state to conduct the trials followed by Chandigarh.